<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>Overview of studies included in this review.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Reference</th>
    <th align="left" rowspan="1" colspan="1">Type of Cancer</th>
    <th align="left" rowspan="1" colspan="1">Oral application</th>
    <th align="left" rowspan="1" colspan="1">Species Name</th>
    <th align="left" rowspan="1" colspan="1">Type of Study</th>
    <th align="left" rowspan="1" colspan="1">Number of Patients</th>
    <th align="left" rowspan="1" colspan="1">Duration of Treatment</th>
    <th align="left" rowspan="1" colspan="1">Parameters</th>
    <th align="left" rowspan="1" colspan="1">Main results</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B55" ref-type="bibr">Valadares et al., 2013</xref>)
    </td>
    <td rowspan="1" colspan="1">Breast cancer, stage II and III receiving chemotherapy</td>
    <td rowspan="1" colspan="1">Extract (2.1 g/day), divided into 2 daily doses (6 tablets per day, 3 in the morning and 3 in the afternoon, between meals) for a period of 6 months</td>
    <td rowspan="1" colspan="1">
     <italic>Agaricus</italic> sylvaticus
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">46</td>
    <td rowspan="1" colspan="1">6 months</td>
    <td rowspan="1" colspan="1">Chemotherapy-associated adverse effects</td>
    <td rowspan="1" colspan="1">Patients in the verum group had reduced chemotherapy-associated adverse effects (nausea, vomiting and anorexia)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B16" ref-type="bibr">Fortes et al., 2008</xref>; 
     <xref rid="B15" ref-type="bibr">Fortes et al., 2009</xref>; 
     <xref rid="B11" ref-type="bibr">Costa Fortes et al., 2010</xref>; 
     <xref rid="B10" ref-type="bibr">Costa Fortes and Carvalho Garbi Novaes, 2011</xref>)
    </td>
    <td rowspan="1" colspan="1">Postsurgical patients with colorectal cancer stages I-III</td>
    <td rowspan="1" colspan="1">Extract (30 mg/kg/day), divided into 2 daily doses (6 tablets per day, 3 in the morning and 3 in the afternoon, between meals)</td>
    <td rowspan="1" colspan="1">
     <italic>Agaricus</italic> sylvaticus
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">56</td>
    <td rowspan="1" colspan="1">6 months</td>
    <td rowspan="1" colspan="1">Blood count, iron, fasting glucose, BMI, blood pressure</td>
    <td rowspan="1" colspan="1">Beneficial effects in the verum group regarding hematological parameters and a reduction of fasting plasma glucose levels and blood pressure. No effects on BMI.</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B50" ref-type="bibr">Tangen et al., 2015</xref>)
    </td>
    <td rowspan="1" colspan="1">Multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation</td>
    <td rowspan="1" colspan="1">Extract, 60 ml/day</td>
    <td rowspan="1" colspan="1">AndoSan (82.4% of 
     <italic>Agaricus blazei</italic> Murill, 14.7% of hericium erinaceus, and 2.9% of grifola frondosa)
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">40</td>
    <td rowspan="1" colspan="1">Intake 7 weeks</td>
    <td rowspan="1" colspan="1">Primary end points: 1) changes in serum levels of cytokines, chemokines, and growth factors in peripheral blood, 2) differences in expression levels of genes involved in immune activation by whole genome assay, both measured on the day of inclusion and at the end of intake of the study product, and 3) differences in the stem cell harvest product of a number of mononuclear cell subsets associated with the immune system. Secondary end points: 1) clinical response to treatment, 2) time in neutropenia, 3) days with body temperature above 38°C, 4) days with IV antibiotics after stem cell infusion, 5) time to new treatment, 6) OS, and 7) quality of life</td>
    <td rowspan="1" colspan="1">In the leukapheresis product harvested after stem cell mobilization, increased percentages of treg cells (CD4
     <sup>+</sup>/CD127d
     <sup>+</sup>/CD25) and plasmacytoid dendritic cells (CD303
     <sup>+</sup>) were found in patients receiving verum. A significant increase in serum levels of IL-1, IL-5 and IL- 7 was observed at the end of treatment in the verum group.Increased expression of immunoglobulin genes, killer immunoglobulin receptor genes and HLA genes were observed in the verum group there were no statistically significant differences in treatment response, OS, time in neutropenia, temperature above 38 °C and time to new treatment in the verum group, trends were observed for a longer median time to next treatment and a shorter duration of IV antibiotic treatment. Health related quality of life assessment revealed no differences between the study groups
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B1" ref-type="bibr">Ahn et al., 2004</xref>)
    </td>
    <td rowspan="1" colspan="1">Cervical, ovarian, endometrial cancer undergoing chemotherapy</td>
    <td rowspan="1" colspan="1">Extract, 3 packs/day, 1 pack per time</td>
    <td rowspan="1" colspan="1">
     <italic>Agaricus blazei</italic> Murill Kyowa
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">100</td>
    <td rowspan="1" colspan="1">Every 3 weeks for at least 3 cycles of chemotherapy</td>
    <td rowspan="1" colspan="1">Immunological status, side effects, quality of life</td>
    <td rowspan="1" colspan="1">Natural killer cell activity was significantly higher in the verum group. No significant difference in lymphokine-activated killer and monocyte activities was observed in a manner similar to the count of specific immune cell populations between the groups. Chemotherapy-associated side effects such as appetite, alopecia, emotional stability, and general weakness were improved by verum only</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B52" ref-type="bibr">Tsai et al., 2016</xref>)
    </td>
    <td rowspan="1" colspan="1">Advanced and/or metastatic adenocarcinoma (breast, gastric, lung, liver, colorectal), previously treated with standard chemotherapy</td>
    <td rowspan="1" colspan="1">Extract, 20 ml, 2×/day</td>
    <td rowspan="1" colspan="1">Antrodia cinnamomea</td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">37</td>
    <td rowspan="1" colspan="1">30 days</td>
    <td rowspan="1" colspan="1">The primary endpoint was 6-months OS; the secondary endpoints were DCR, QoL and biochemical parameters</td>
    <td rowspan="1" colspan="1">Mean OSs were 5.4 months for the verum group and 5.0 months for the placebo group (
     <italic>p</italic> = 0.340), and the DCRs were 41.2 and 55%, respectively (
     <italic>p</italic> = 0.33). Most hematologic, liver, or kidney functions did not differ significantly between the two groups, but platelet counts were lower in the verum group than in the placebo group (
     <italic>p</italic> = 0.02). QoL assessments were similar in the two groups, except that the verum group showed significant improvements in quality of sleep (
     <italic>p</italic> = 0.04)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B9" ref-type="bibr">Chay et al., 2017</xref>)
    </td>
    <td rowspan="1" colspan="1">Advanced hepatocellular carcinoma</td>
    <td rowspan="1" colspan="1">Extract, 2.4 g/day</td>
    <td rowspan="1" colspan="1">Coriolus versicolor</td>
    <td rowspan="1" colspan="1">RCT - 2:1 to either verum or placebo</td>
    <td rowspan="1" colspan="1">15</td>
    <td rowspan="1" colspan="1">Median treatment time 2.5–4.2 months</td>
    <td rowspan="1" colspan="1">The primary endpoint was the median TTP between both arms. Secondary endpoints include evaluating response rates, toxity, qol, PFS and OS.</td>
    <td rowspan="1" colspan="1">There was no difference in TTP with use of verum compared to placebo. Verum had better social and emotional functioning scores and less appetite loss and pain symptoms compared to placebo subjects during treatment</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B67" ref-type="bibr">Zhao et al., 2012</xref>)
    </td>
    <td rowspan="1" colspan="1">Breast cancer patients with cancer-related fatigue undergoing endocrine therapy</td>
    <td rowspan="1" colspan="1">Spore powder, 1 g 3×/day for 4 weeks</td>
    <td rowspan="1" colspan="1">
     <italic>Ganoderma lucidum</italic>
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled</td>
    <td rowspan="1" colspan="1">48</td>
    <td rowspan="1" colspan="1">4 weeks</td>
    <td rowspan="1" colspan="1">FACT-F, HADS, EORTC QLQ-C30, TNF-α, IL-6</td>
    <td rowspan="1" colspan="1">The verum group showed statistically significant improvements in the domains of physical well-being, fatigue and overall quality of life and less anxiety/depression after intervention compared to placebo. TNF-
     <italic>α</italic> and IL-6 were lower in the verum group compared to placebo
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B39" ref-type="bibr">Oka et al., 2010</xref>)
    </td>
    <td rowspan="1" colspan="1">Colorectal adenoma</td>
    <td rowspan="1" colspan="1">Extract, 1.5 g/day</td>
    <td rowspan="1" colspan="1">
     <italic>Ganoderma lucidum</italic>
    </td>
    <td rowspan="1" colspan="1">CCT</td>
    <td rowspan="1" colspan="1">198</td>
    <td rowspan="1" colspan="1">12 months</td>
    <td rowspan="1" colspan="1">Size, site and macroscopic type of all adenomas</td>
    <td rowspan="1" colspan="1">The changes in the number of adenomas up to 12 months increased to 0.66 ± 0.10 in the control group, while decreasing in the verum group to −0.42 ± 0.10 (
     <italic>p</italic> &lt; 0.01). The total size of adenomas increased to 1.73 ± 0.28 mm in the control group and decreased to −1.40 ± 0.64 mm in the verum group (
     <italic>p</italic> &lt; 0.01)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">(
     <xref rid="B19" ref-type="bibr">Gao et al., 2003a</xref>)
    </td>
    <td rowspan="1" colspan="1">Advanced lung cancer</td>
    <td rowspan="1" colspan="1">Extract, 600 mg 3×/day</td>
    <td rowspan="1" colspan="1">
     <italic>Ganoderma lucidum</italic>
    </td>
    <td rowspan="1" colspan="1">RCT, placebo-controlled, double-blind</td>
    <td rowspan="1" colspan="1">68</td>
    <td rowspan="1" colspan="1">12 weeks</td>
    <td rowspan="1" colspan="1">Karnofsky performance status, immunological parameters </td>
    <td rowspan="1" colspan="1">Treatment with verum showed a stable disease in 35% lung cancer patients at the 12-weeks visit, which was significantly higher than in the control group (22%). Treatment with verum resulted in a significant increase in karnofsky scores (&gt;10 scores) in 50% of the patients compared to placebo (14% in placebo group) cancer-related symptoms (e.g., fever, cough, weakness, sweating and insomnia) were significantly improved in 43–84% of cancer patients receiving verum compared to placebo (11–43%). Verum showed a significant increase in lymphocyte mitogenic reactivity to concanavalin A, CD3 percentage and natural killer cell activity compared to placebo</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>RCT, Randomized Controlled Trial; CCT, Controlled Clinical Trial; BMI, Body Mass Index; OS, overall survival; DCR, disease control rate; QoL, quality of life; TTP, time to progression; PFS, progression-free survival; EORTC-QLQC30, European organization for research and treatment - quality of life questionnaire; HADS, Hospital Anxiety and Depression Scale; FACT-Hep, Functional Assessment of Cancer Therapy - Hepatobiliary Cancer; IV, intravenous; CD, cluster of differentiation; IL, interleukin; TNF, tumor necrosis factor</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
